2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.097 Husam_Albarmawi_NACLC23

PP01.097 Husam_Albarmawi_NACLC23_Abstract

Pdf Summary

The abstract describes a study investigating the treatment patterns of patients with resected non-small cell lung cancer (NSCLC) who received adjuvant atezolizumab. Atezolizumab is a approved as adjuvant treatment for adults with stage II-IIIA NSCLC and PD-L1 1% based on the IMpower010 trial. The study used a retrospective observational cohort design and included adults with incident lung cancer. Patients were required to have continuous enrollment 3 months pre- and post-index, lung surgery 12 months post-index, and a claim for atezolizumab. Patients receiving atezolizumab for recurrent/metastatic disease were excluded. Treatment patterns were analyzed descriptively and atezolizumab discontinuation was assessed using Kaplan-Meier methods. <br /><br />The results showed that 119 patients received adjuvant atezolizumab, with a median age of 63 years. Most patients (79%) received adjuvant chemotherapy before starting atezolizumab. The mean duration of adjuvant atezolizumab was 48.6 weeks, with 80% of patients still on treatment at 26 weeks and 76% at 39 weeks. These findings suggest that the real-world duration of adjuvant chemotherapy and atezolizumab is comparable to the IMpower010 trial, indicating that patients are potentially recurrence-free and tolerating treatment. <br /><br />In conclusion, this study provides insight into the real-world treatment patterns of patients with resected NSCLC receiving adjuvant atezolizumab. The results suggest that the majority of patients continue treatment for a significant duration, supporting the effectiveness and tolerability of this adjuvant therapy. Further research is needed to confirm these findings and explore long-term outcomes.

Keywords

resected non-small cell lung cancer

adjuvant atezolizumab

treatment patterns

IMpower010 trial

retrospective observational cohort design

incident lung cancer

continuous enrollment

lung surgery

atezolizumab discontinuation

real-world duration